Market Overview

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aradigm Corporation of Class Action Lawsuit and Upcoming Deadline – ARDM

Share:

Pomerantz LLP announces that a class action lawsuit has been filed
against Aradigm Corporation ("Aradigm" or the "Company") (NASDAQ:ARDM)
and certain of its officers. The class action, filed in United States
District Court, for the Northern District of California, and docketed
under 18-cv-00261, is on behalf of a class consisting of investors who
purchased or otherwise acquired the securities of Aradigm between July
27, 2017 and January 8, 2018, both dates inclusive (the "Class Period").
Plaintiff seeks to recover compensable damages caused by Defendants'
violations of the federal securities laws and to pursue remedies under
Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the
"Exchange Act") and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased Aradigm securities between July
27, 2017, and January 8, 2018, both dates inclusive, you have until
March 12, 2018, to ask the Court to appoint you as Lead Plaintiff for
the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com
or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who
inquire by e-mail are encouraged to include their mailing address,
telephone number, and quantity of shares purchased.

[Click
here to join this class action]

Aradigm Corporation develops novel pulmonary drug delivery systems. The
Company's systems are designed to enhance the delivery and effectiveness
of a number of existing and development stage drugs and reduce the need
for injectable drug therapy.

On July 27, 2017, Aradigm submitted a New Drug Application ("NDA") to
the U.S. Food and Drug Administration ("FDA") for U.S. marketing
approval for Linhaliq for the treatment of non-cystic fibrosis
bronchiectasis patients with chronic lung infections.

The Complaint alleges that throughout the Class Period, Defendants made
materially false and misleading statements regarding the Company's
business, operational and compliance policies. Specifically, Defendants
made false and/or misleading statements and/or failed to disclose that:
(i) the methodology underlying Aradigm's Linhaliq Phase III clinical
trials was not well tailored to yield consistent efficacy findings or to
provide data sufficient to account for discordant efficacy findings;
(ii) the endpoint of the Phase III trials—namely, delaying the time to
first exacerbation on study therapy compared to placebo over
approximately one year of observation—was unlikely to demonstrate a
clinically meaningful benefit with respect to a patient population that
would likely be taking the drug for a longer duration; (iii)
accordingly, these studies were unlikely to support FDA approval of the
Linhaliq NDA; and (iv) as a result, Aradigm's public statements were
materially false and misleading at all relevant times.

On January 9, 2018, the FDA announced that it would discuss Aradigm's
Linhaliq NDA at the Antimicrobial Drugs Advisory Committee meeting
scheduled for January 11, 2018. The FDA stated that "[r]easons for the
discordance in efficacy findings between trials cannot be explained
based on the information collected in the two trials" underlying the
Linhaliq NDA and that, with respect to the clinical trials' endpoint,
"it is unclear that delaying the time to first exacerbation on study
therapy compared to placebo over approximately one year of observation
translates into a clinically meaningful benefit for a patient population
that would most likely be on this therapy for long durations."

On this news, Aradigm's share price fell $2.28, or 38.12%, to close at
$3.70 per share on January 9, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and
Paris, is acknowledged as one of the premier firms in the areas of
corporate, securities, and antitrust class litigation. Founded by the
late Abraham L. Pomerantz, known as the dean of the class action bar,
the Pomerantz Firm pioneered the field of securities class actions.
Today, more than 80 years later, the Pomerantz Firm continues in the
tradition he established, fighting for the rights of the victims of
securities fraud, breaches of fiduciary duty, and corporate misconduct.
The Firm has recovered numerous multimillion-dollar damages awards on
behalf of class members. See www.pomerantzlaw.com.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com